All In Biotech

Drug Trial Radar · NCT07065682

Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Jul 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jul 1, 2023

Primary completion

Dec 1, 2024

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Universitas DiponegoroAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a double blinded RCT with pre-post test design on the effect of combination of dutasteride and aloe vera, compared to dutasteride only, on uroflowmetry results, prostate volume, and VEGF serum level among patients with benign prostate hyperplasia. The treatment was given for 12 weeks

Conditions

  • BPH (Benign Prostatic Hyperplasia)

Interventions

  • Aloevera + dutasterideDrug

    Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day

  • Dutasteride (0.5mg)Drug

    Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uroflowmetry resultTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RSUD Karawang

    Karawang, West Java, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.